Tag: medicine

Tokyo, Japan and Cambridge, UK, 2 June 2026 – Nxera Pharma Co., Ltd. (“Nxera” or the “Company”)　 announces that the Ministry of Food and Drug Safety (MFDS) of the Republic of Korea has granted Orphan Drug Designation (ODD) and Global Innovative Products on Fast Track (GIFT) designation to vamorolone for the treatment of Duchenne muscular dystrophy (DMD). The Company plans to submit a Marketing Authorization Application (MAA) for vamorolone in South Korea during 2026.

PITTSBURGH, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Langdon & Company, LLP (“Langdon & Company”) recently announced a cybersecurity incident, which impacted the personal information of forty-six thousand individuals connected to its client, Easterseals North Carolina and Virginia.¹ The information potentially impacted in the data breach includes individuals’ names, addresses, dates of birth, Taxpayer identification number, Social Security number, financial account information, medical information, health insurance information, and/or digital signature.

FUKUOKA, Japan, Aug. 15, 2025 (GLOBE NEWSWIRE) -- rYojbaba Co., Ltd. (Nasdaq: RYOJ) (“rYojbaba” or the “Company”), a Japanese labor consulting and health services company, today announced the closing of its initial public offering of 1,250,000 Japanese common shares at a public offering price of US$4.00 per share. The total gross proceeds from the offering, before deducting underwriting discounts and other offering expenses payable by rYojbaba, was US$5 million. rYojbaba’s Japanese common shares began trading on the Nasdaq Capital Market on August 14, 2025, under the ticker symbol “RYOJ”.

EMERYVILLE, Calif., Aug. 15, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on August 12, 2025, the compensation committee of the Company’s board of directors granted three new non-executive employees 58,900 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company’s 2025 Employment Inducement Award Plan, which was approved by the Company’s board of directors in February 2025 under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.

Transaction Expected to Close in the Coming Days

Tonmya is the first FDA-approved therapy for the treatment of fibromyalgia in over 15 years

Introducing Aira Health: Thoughtfully Formulated Supplements for Women’s Wellness

The stem cell banking market is booming due to advancements in tech and regenerative medicine, rising healthcare spend, private investments, and ethical shifts favoring adult stem cells. Key opportunities lie in personalized healthcare, clinical trials, and expanding access globally, with North America leading market growth.